WallStreetZenWallStreetZen

NASDAQ: ATRA
Atara Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ATRA

Based on 3 analysts offering 12 month price targets for Atara Biotherapeutics Inc.
Min Forecast
$11.00+40.31%
Avg Forecast
$14.00+78.57%
Max Forecast
$18.00+129.59%

Should I buy or sell ATRA stock?

Based on 3 analysts offering ratings for Atara Biotherapeutics Inc.
Hold
Strong Buy
1 analysts 33.33%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
1 analysts 33.33%

Be the first to know when Wall Street analysts revise their ATRA stock forecasts and price targets.

ATRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-16
lockedlocked$00.00+00.00%2024-08-13
lockedlocked$00.00+00.00%2024-07-17

1 of 1

Forecast return on equity

Is ATRA forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is ATRA forecast to generate an efficient return on assets?
Company
N/A
Industry
26.37%

ATRA earnings per share forecast

What is ATRA's earnings per share in the next 2 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$12.09
Avg 2 year Forecast
-$16.61

ATRA revenue forecast

What is ATRA's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$92.1M+47.63%
Avg 2 year Forecast
$61.8M-0.94%
ATRA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ATRA revenue growth forecast

How is ATRA forecast to perform vs Biotechnology companies and vs the US market?
Company
-20.37%
Industry
35.48%
Market
9.73%
ATRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ATRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ATRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ATRA$7.84$14.00+78.57%Hold
NXTC$1.38$6.00+334.78%Buy
PASG$0.61$13.00+2,024.18%Strong Buy
BLRX$0.47$11.50+2,352.03%Strong Buy
LTRN$3.69N/AN/A
View Top Biotech Stocks

Atara Biotherapeutics Stock Forecast FAQ

Is Atara Biotherapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: ATRA) stock is to Hold ATRA stock.

Out of 3 analysts, 1 (33.33%) are recommending ATRA as a Strong Buy, 1 (33.33%) are recommending ATRA as a Buy, 0 (0%) are recommending ATRA as a Hold, 0 (0%) are recommending ATRA as a Sell, and 1 (33.33%) are recommending ATRA as a Strong Sell.

If you're new to stock investing, here's how to buy Atara Biotherapeutics stock.

What is ATRA's earnings growth forecast for 2024-2025?

(NASDAQ: ATRA) Atara Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.64%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.7%.

Atara Biotherapeutics's earnings in 2024 is -$181,048,000.On average, 3 Wall Street analysts forecast ATRA's earnings for 2024 to be -$59,422,942, with the lowest ATRA earnings forecast at -$86,013,358, and the highest ATRA earnings forecast at -$10,518,205.

In 2025, ATRA is forecast to generate -$81,655,184 in earnings, with the lowest earnings forecast at -$100,709,354 and the highest earnings forecast at -$67,581,924.

What is ATRA's revenue growth forecast for 2024-2025?

(NASDAQ: ATRA) Atara Biotherapeutics's forecast annual revenue growth rate of -20.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.73%.

Atara Biotherapeutics's revenue in 2024 is $62,387,000.On average, 2 Wall Street analysts forecast ATRA's revenue for 2024 to be $452,676,013, with the lowest ATRA revenue forecast at $374,526,734, and the highest ATRA revenue forecast at $530,825,292.

In 2025, ATRA is forecast to generate $303,750,028 in revenue, with the lowest revenue forecast at $275,242,744 and the highest revenue forecast at $332,257,312.

What is ATRA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ATRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 26.37%.

What is ATRA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ATRA price target, the average ATRA price target is $14.00, with the highest ATRA stock price forecast at $18.00 and the lowest ATRA stock price forecast at $11.00.

On average, Wall Street analysts predict that Atara Biotherapeutics's share price could reach $14.00 by Aug 16, 2025. The average Atara Biotherapeutics stock price prediction forecasts a potential upside of 78.57% from the current ATRA share price of $7.84.

What is ATRA's Earnings Per Share (EPS) forecast for 2024-2025?

(NASDAQ: ATRA) Atara Biotherapeutics's current Earnings Per Share (EPS) is -$39.35. On average, analysts forecast that ATRA's EPS will be -$12.09 for 2024, with the lowest EPS forecast at -$17.50, and the highest EPS forecast at -$2.14. In 2025, ATRA's EPS is forecast to hit -$16.61 (min: -$20.49, max: -$13.75).

What is ATRA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ATRA) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.